Disseminated Intravascular Coagulation in Solid Tumors: Clinical and Pathologic Study

Summary

Disseminated intravascular coagulation (DIC) is a well known hemostatic complication of solid tumors. We evaluated the occurrence of DIC in 1117 patients with solid tumors. Of these patients, 76 (6.8%) were diagnosed with DIC. There were a total of 145 bleeding and clotting episodes reported in the 76 patients. Thrombocytopenia, hypofibrinogemia, elevated D-dimer and fibrinogen degradation products were the most common coagulation abnormalities encountered in patients with DIC. In multivariate analysis, older age (p = .0001), male gender (p = .009), advanced malignancies (p = .027), breast cancer (p = .038) and the presence of necrosis in the tumor specimen (p = .004), emerged as independent factors significantly related to the occurrence of DIC in patients with solid tumors. Of the 76 patients, 25 (33%) achieved response to treatment of DIC as defined in the study. Patients with early stage and advanced malignancies who developed DIC had inferior survival when compared with their counterparts without DIC (p = .039 and p = .005, respectively). Taken together, this study indicates that certain clinical and laboratory features are more common in patients with solid tumors who developed DIC. The occurrence of DIC appears to have an independent effect on survival of patients with cancer. Cooperative studies are encouraged to better address the usefulness and optimal prophylactic heparin regimen in patients at risk for DIC.

Keywords

Disseminated intravascular coagulation - fibrinolysis - cancer

• References

• 1 Levi M, ten Cate H. Disseminated intravascular coagulation. N Eng, J Med 1999; 341: 586-92.
• 2 Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
• 3 Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. Br Med J 1996; 312: 683-7.
• 4 ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-7.
• 5 Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Haemost 1998; 24: 3-15.
• 6 Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, Gordon SG, Barbui T. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92: 142-51.
• 7 Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 2000; 18: 191-6.
• 8 Contrino J, Hair G, Kreutzer DI, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast cancer. Nat Med 1996; 2: 209-15.
• 9 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastases by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
• 10 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
• 11 Stouthard J, Levi M, Hack CE, Veenhof CHN, Romijin JA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation but not fibrinolysis in humans. Thromb Haemost 1996; 76: 738-42.
• 12 Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusion have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74: 165-72.
• 13 Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990; 17: 172-86.
• 14 Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Haemost 1996; 22: 2159-78.
• 15 Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined over expression of urokinase, urokinase receptor and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign and malignant breast tissues. Cancer 1996; 77: 1079-88.
• 16 Takahoshi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1994; 46: 33-7.
• 17 Lissoni P, Ardizzoia A, Barni S, Pittalis S, Rossini F, Porta A, Tancini G. Characterization of cancer-related disseminated intravascular coagulation in relation to tumor necrosis factor-alpha blood concentration: possible therapeutic role of pentoxifylline. Tumori 1996; 82: 78-80.
• 18 Nand S, Fischer SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987; 3: 1998-2003.